SCNX · Scienture Holdings, Inc.
The latest filing states the doubt was alleviated.
“While these factors initially indicated substantial doubt about the ability of the Company to continue as a going concern, management believes that its existing cash on hand, revenues from the commercialization of ARBLI™ (SCN-102) and REZENOPY™ (SCN-110) and its planned financing activities alleviate that doubt.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 22, 2023; bars on opposite sides are not compared.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$2,134,705 | the three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net loss -$2,822,371
+$461,571 Depreciation and amortization
+$269,785 Interest expense
-$147,147 Other non-operating expenses (income)
+$103,457 Stock based compensation (non-cash)
= Adjusted EBITDA -$2,134,705
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Pharmaceutical Retailers — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SCNX
this stock
Scienture Holdings, Inc.
|
$16.18M | -22.7% | +30.7% | — | 3.9% |
|
RTEZ
REST EZ Inc.
|
$4.20B | — | -100.0% | — | 0.0% |
|
HITI
High Tide Inc.
|
$220.55M | -5.3% | — | — | 0.7% |
|
SHFH
Scientist Home Future Health Ltd
|
$189.73M | — | — | — | — |
|
BHIC
BioScience Health Innovations, Inc.
|
$58.53M | — | +208.3% | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 22, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SCNX | -12.4% | +3.5% | +1.3% | +3.5% | -22.8% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -12.9% | +0.5% | -12.1% | +0.5% | -35.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.